Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background & Aims: Our retrospective study has suggested encouraging outcomes of lenvatinib combined with PD-1 inhibitor and transarterial chemoembolization (TACE) on advanced hepatocellular carcinoma (HCC). This phase II trial was conducted to prospectively investigate the efficacy and safety of lenvatinib, sintilimab (a PD-1 inhibitor) plus TACE (Len-Sin-TACE) in patients with advanced stage HCC.
Methods: This was a single-arm phase II trial. Patients with BCLC stage C HCC were recruited. They received lenvatinib (bodyweight ≥60 kg, 12 mg; bodyweight <60 kg, 8 mg) orally once daily, sintilimab (200 mg) intravenously once every 3 weeks, and on demand TACE. The primary endpoint was progression-free survival (PFS) per mRECIST.
Results: Thirty patients were enrolled. The primary endpoint was met with a median PFS of 8.0 (95% confidence interval [CI]: 6.1-9.8) months per mRECIST, which was the same as that per RECIST 1.1. The objective response rate was 60.0% per mRECIST and 30.0% per RECIST 1.1. The disease control rate was 86.7% per mRECIST/RECIST 1.1. The median duration of response was 7.4 (95% CI: 6.6-8.2) months per mRECIST (n = 18) and 4.3 (95% CI: 4.0-4.6) months per RECIST 1.1 (n = 9). The median overall survival was 18.4 (95% CI: 14.5-22.3) months. Treatment-related adverse events (TRAEs) occurred in 28 patients (93.3%) and grade 3 TRAEs were observed in 12 patients (40.0%). There were no grade 4/5 TRAEs.
Conclusions: Len-Sin-TACE showed promising antitumour activities with a manageable safety profile in patients with advanced stage HCC. The preliminary results need to be further evaluated with phase III randomized trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/liv.15831 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and clinical efficacy of immune checkpoint inhibitors in pediatric hepatocellular carcinoma: a case report and review of the literature.
Front Oncol
August 2025
Department of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Background: Pediatric hepatocellular carcinoma (HCC) is rare, with surgical resection and liver transplantation as primary treatments. No standard options exist for unresectable/metastatic disease. Although immune checkpoint inhibitors (ICIs) show efficacy in adults, their pediatric safety and efficacy remain unestablished.
View Article and Find Full Text PDFTargeting metabolic and epigenetic reprogramming in metastatic fumarate hydratase-deficient renal cell carcinoma.
Clin Exp Metastasis
August 2025
Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
Fumarate hydratase-deficient renal cell carcinoma (FHdRCC) has been classified under the new category of molecularly defined RCCs according to the WHO classification 2022. Although rare, FHdRCC is an aggressive malignancy with a high metastatic potential and poor prognosis, even at early stages. Due to its low incidence, no standard therapeutic regimen has been established to date.
View Article and Find Full Text PDFSintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, single-center study.
Sci Rep
July 2025
Department of Oncology, The First People's Hospital of Yibin, Yibin, 644000, Sichuan, China, 65 Wenxing Street.
This study was designed to assess the safety and efficacy of Sintilimab plus Lenvatinib in combination with transarterial chemoembolization (TACE) and subsequent radiofrequency ablation (RFA) in the treatment of unresectable hepatocellular carcinoma (HCC). A retrospective data analysis was conducted on 21 patients diagnosed with HCC at Yibin First People's Hospital, between February 2021 and July 2022. These patients met the eligibility criteria and underwent TACE followed by RFA.
View Article and Find Full Text PDFTransarterial chemoembolization in combination with lenvatinib and sintilimab for the treatment of unresectable hepatocellular carcinoma with arterioportal shunts: a retrospective analysis.
Transl Cancer Res
June 2025
Interventional Therapy Department, Ningbo No. 2 Hospital, Ningbo, China.
Background: The efficacy of transarterial chemoembolization (TACE) in treating unresectable hepatocellular carcinoma (uHCC) complicated by arterioportal shunts (APS) was unsatisfactory. Developed systemic therapies can synergize with TACE, potentially reducing APS recanalization and enhancing patient benefits. The objective of this study was to evaluate and compare the therapeutic efficacy and safety of a combination therapy regimen that includes TACE, lenvatinib, and sintilimab (TACE-L-S) versus TACE monotherapy in uHCC patients with APS.
View Article and Find Full Text PDFUpdated Network Meta-Analysis of First-Line Systemic Treatments for Advanced HCC: Consistent Role of TACE.
Liver Cancer
June 2025
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Background And Aims: We conducted an updated network meta-analysis to evaluate and identify the optimal first-line treatment for advanced hepatocellular carcinoma (HCC) among all relevant interventional and targeted therapies.
Methods: We analyzed 16 phase 2 or 3 randomized controlled trials involving 9,482 patients with metastatic or unresectable HCC published between 2018 and 2024. The trials evaluated 11 systemic agents and 5 interventional treatments in combination with systemic therapy, using either sorafenib or lenvatinib as the control.